Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Enzyme replacement therapy (recombinant iduronate-2-sulfatase)

Idursulfase

Elaprase

Dosage form
Tablet
Available strengths
2 mg/mL (6 mg/3 mL vial)
Drug class
Enzyme replacement therapy (recombinant iduronate-2-sulfatase)
Common brand
Elaprase

Clinical overview. Idursulfase (Elaprase) is a recombinant enzyme replacement therapy given by weekly intravenous infusion for long-term treatment of Hunter syndrome (mucopolysaccharidosis II). Infusion-related reactions such as rash, itching, fever, and flushing are common, especially early in treatment, and tend to lessen over time. Serious anaphylactic reactions can occur, sometimes years into therapy, so infusions require medical supervision and monitoring.

Indication

Common therapeutic uses

  • Idursulfase is used for long-term enzyme replacement therapy in patients with Hunter syndrome (mucopolysaccharidosis II, MPS II).

Pregnancy

Risk assessment and monitoring considerations

  • There are no data on idursulfase use in pregnant women; animal studies show that idursulfase crosses into fetal circulation.
  • Idursulfase should not be given during pregnancy except when the clinical need is clear and the potential benefit is judged to substantially outweigh the risk.

Breastfeeding

Infant exposure considerations

  • Animal studies show idursulfase is excreted in breast milk, so caution should be used when giving idursulfase to a nursing woman after weighing the risks and benefits.

Geriatrics

Dosing and tolerability considerations

  • Studies in patients over 65 years of age have not been performed, so safety and efficacy in this population are not established.

Pediatrics

Use in children and adolescents

  • Clinical studies included patients as young as 16 months of age, and children, adolescents, and adults responded similarly to treatment.
  • Pediatric patients with the complete-deletion, large-rearrangement genotype have a higher probability of developing antibodies, including neutralizing antibodies, and infusion-related events, along with a more muted treatment response.

Dosage & Administration

Practical dosing and administration

  • The recommended dose is 0.5 mg/kg body weight given once weekly by intravenous infusion.
  • The infusion is given over 3 hours initially, which may be gradually reduced to 1 hour if well tolerated; infusion time should never exceed 8 hours.
  • The initial infusion rate is 8 mL/hr for the first 15 minutes, increased by 8 mL/hr every 15 minutes if tolerated, but never exceeding 100 mL/hr.
  • The infusion rate may be slowed or temporarily stopped if an infusion-related reaction occurs.
  • The calculated dose must be diluted in 100 mL of 0.9% sodium chloride injection using strict aseptic technique, and administered through a 0.2 micrometer in-line filter without mixing with other products.
  • Diluted solution should be used within 8 hours at room temperature or within 24 hours if refrigerated.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose experience is limited to a single reported case.
  • In that case, a patient who received idursulfase at twice the recommended dose for about 1.5 years developed two anaphylactic reactions occurring several years after starting treatment.

Common side effects

Frequently reported tolerability concerns

  • Headache is very common.
  • Fever (pyrexia) is very common.
  • Rash is very common.
  • Itching (pruritus) is very common.
  • Hives (urticaria) is very common.
  • Chest pain is very common.
  • Hypertension is very common.
  • Infusion site swelling is common.
  • Nausea is common.
  • Dyspepsia (indigestion) is common.
  • Abdominal pain is common.
  • Diarrhea is common.
  • Cough is common.
  • Wheezing is common.
  • Flushing is common.
  • Dizziness is common.
  • Upper respiratory tract infection is common in children.
  • Muscle or bone pain may occur.
  • Nasal congestion and sore throat may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Anaphylactoid or anaphylactic reactions, which can be life-threatening, have occurred up to several years after starting treatment, and late-emergent symptoms can appear as long as 24 hours after an initial reaction.
  • Hypoxic episodes requiring oxygen therapy have occurred during infusions, particularly in patients with underlying obstructive airway disease.
  • A seizure occurred in one patient during an infusion given while the patient had a febrile respiratory illness.
  • Serious exacerbation of respiratory or cardiac status can occur during infusion in patients susceptible to fluid overload or with compromised cardiac or respiratory function.
  • Angioedema has been reported as part of allergic reactions to idursulfase.
  • Cardiac arrhythmia and rapid or irregular heartbeat have been reported during or after infusion.
  • Pulmonary embolism has been reported in a patient with pre-existing cardiac disease.
  • Fatal outcomes have been reported, including cardiac failure, cardiorespiratory arrest, pneumonia, respiratory distress, and respiratory failure.
  • About half of treated patients develop anti-idursulfase antibodies, which can reduce the drug's effect on clearing glycosaminoglycans (GAG).
  • Seek urgent medical attention for difficulty breathing, wheezing, swelling of the face or throat, chest pain, seizures, or a rapid drop in blood pressure during or after an infusion.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients susceptible to fluid overload, or those with compromised cardiac or respiratory function requiring fluid restriction.
  • Use with caution in patients with severe underlying airway disease, who should be closely monitored in an appropriate clinical setting with supplemental oxygen readily available.
  • Use with caution and consider delaying infusion in patients with an acute febrile respiratory illness.
  • Use with caution regarding antihistamine and other sedative medications in patients with respiratory compromise, since these can complicate management of infusion reactions.
  • Use with caution in patients who previously developed hypersensitivity reactions; re-treatment is at the discretion of the healthcare provider after successful management of symptoms.
  • No studies have been conducted in patients with hepatic or renal impairment, so caution is warranted in these populations.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to idursulfase or to any ingredient in the formulation or container.

Drug interactions

Clinically relevant combinations

  • No formal drug interaction studies have been conducted with idursulfase.
  • Based on its breakdown by cellular lysosomal proteolysis, idursulfase is not expected to be involved in cytochrome P450-mediated drug interactions.

Food interactions

Meal-related administration

  • No food interactions have been established for this intravenous enzyme replacement therapy.

Time of administration

Practical scheduling

  • Idursulfase is administered once weekly by intravenous infusion under medical supervision, not tied to meals or a specific time of day.

Storage

Product handling

  • Store at 2°C to 8°C (refrigerated), protected from light; do not freeze or shake.
  • Do not use after the expiration date on the vial.

Patient take-away

Key counselling points for a quick closing summary

  • Elaprase is a weekly intravenous enzyme replacement infusion for Hunter syndrome (MPS II), given under medical supervision, typically over 1 to 3 hours.
  • Infusion-related reactions such as rash, itching, fever, and flushing are common, especially early in treatment, and tend to decrease with continued use.
  • Serious allergic reactions can occur, sometimes years into treatment and even hours after the infusion ends, so seek urgent care for breathing difficulty, facial swelling, or severe chest pain.
  • Tell your healthcare professional about any breathing problems, heart conditions, or previous reactions to Elaprase before each infusion.

References

Source material and product information

  1. Health Canada Product Monograph — Idursulfase

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.